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About 20% of patients with a history of atherosclerotic 
cardiovascular disease will experience further cardiovascular 
events despite maximal pharmacological treatment with 
cardioprotective drugs. This highlights the presence of residual 
cardiovascular risk in a significant proportion of patients and the 
need for novel, more effective therapies. These therapies should 
ideally target different pathophysiological pathways involved in 
the onset and the progression of atherosclerosis, particularly the 
inflammatory and immune pathways. Methotrexate is a first-
line disease-modifying antirheumatic drug that is widely used 
for the management of autoimmune and chronic inflammatory 
disorders. There is some in vitro and in vivo evidence that 
methotrexate might exert a unique combination of anti-
inflammatory, blood pressure lowering, and vasculoprotective 
effects. Pending the results of large prospective studies 
investigating surrogate end-points as well as morbidity and 
mortality, repurposing methotrexate for cardiovascular risk 
management might represent a cost-effective strategy with 
immediate public health benefits. This review discusses the 
current challenges in the management of cardiovascular 
disease; the available evidence on the effects of methotrexate 
on inflammation, blood pressure, and surrogate markers of 
arterial function; suggestions for future research directions; and 
practical considerations with the use of methotrexate in this 
context.
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Introduction
Atherosclerotic cardiovascular disease, particularly in the form 
of ischaemic heart disease and stroke, is the leading cause 
of morbidity and mortality worldwide. In 2013, the global 
risk of premature death between the ages of 30 and 70 years 
attributable to cardiovascular disease was 10.8% for men 
and 6.7% for women. The risk was highest for men in Eastern 
Europe and for women in Oceania and lowest for both men and 
women in high-income Asia-Pacific regions.1 In 2015, ischaemic 
heart disease was the leading cause of health loss globally, 
with an estimated 7.3 million acute myocardial infarctions 
and 110.5 million prevalent cases of ischaemic heart disease. 
The prevalence of ischaemic heart disease was 290 cases 
per 100,000 for those 40 to 44 years of age and 11,203 cases 
per 100,000 for those 75 to 79 years of age. In the same year, 
there were an estimated 5.4 million acute first-ever ischaemic 
strokes. The prevalence of stroke was highest for those 74 to 
79 years of age.2
Significant advances in the understanding of the 
pathophysiology of atherosclerosis have led to the concept 
that this disease process is characterized by a state of chronic 
inflammation, immune activation, and oxidative stress of 
the arterial wall.3 There is also good evidence that, at some 
stage, virtually all cardiovascular risk factors trigger these 
events, favouring the onset of endothelial dysfunction and 
vascular damage.4,5 For these reasons, barring the recently 
introduced proprotein convertase subtilisin/kexin type 9 
(PCSK9) inhibitors,6 current cardiovascular drug discovery 
and development programmes are focused on agents that 
modulate the inflammatory and immune pathways, in addition 
Mangoni AA, Tommasi S, Zinellu A, Sotgia S, Carru C, Piga M, Erre GL. Drugs in Context 2018; 7: 212557. DOI: 10.7573/dic.212557 2 of 12
ISSN: 1740-4398
REVIEW – Methotrexate for cardiovascular risk management drugsincontext.com
to exhibiting antiatherosclerotic and vasculoprotective 
effects.7–9 However, the identification of such effects in drugs 
that are currently marketed would avoid the need for expensive, 
high-risk, and time-consuming drug development programmes, 
providing at the same time immediate public health benefits.7
This review will discuss the presence of residual cardiovascular 
risk as a key challenge in the contemporary management of 
atherosclerotic cardiovascular disease, the ongoing search 
for new antiatherosclerotic agents with additional anti-
inflammatory effects, the emerging evidence supporting the 
potential repurposing of the disease-modifying antirheumatic 
drug (DMARD) methotrexate in this context, the opportunities 
for further research in this area, and the practical advantages 
of methotrexate treatment in the routine management of 
cardiovascular patients.
Residual cardiovascular risk
Despite maximal treatment with established cardioprotective 
drug classes, for example, statins, beta-blockers, antiplatelet 
agents, anticoagulants, angiotensin converting enzyme 
(ACE) inhibitors, and angiotensin receptor blockers (ARBs), a 
significant number of patients with a previous atherosclerotic 
cardiovascular event will experience further events. Stone 
and colleagues prospectively studied 697 patients with acute 
coronary syndrome undergoing successful percutaneous 
coronary intervention. Upon hospital discharge, 97% were 
on aspirin, 97% on thienopyridines, 85% on statins or other 
lipid-lowering drugs, 91% on beta-blockers, and 69% on 
ACE inhibitors or ARBs. Barring thienopyridines, the use of 
cardioprotective drugs remained high, between 71 and 92%, 
during the follow up. However, the 3-year cumulative rate 
of further atherosclerotic cardiovascular events was 20%.10 
Similarly, Kaasenbrood and colleagues assessed the 10-year 
risk of recurrent vascular events in 6,904 patients with vascular 
disease. After optimal control of conventional risk factors, 
as per current guideline recommendations, patients with 
vascular disease in different arterial territories had a median 
estimated residual risk of 22% (interquartile range 14 to 36%).11 
Issues with poor treatment adherence in this patient group 
notwithstanding,12 the available evidence suggests that 
approximately one in five patients with high cardiovascular risk 
and overt atherosclerotic cardiovascular disease will experience 
further cardiovascular events despite optimal pharmacological 
management. This observation, and the currently accepted 
hypothesis that atherosclerosis is an inflammatory state of the 
arterial wall, has led to the search for novel, more effective 
agents targeting atherosclerosis.
Targeting inflammation and 
immunity in atherosclerosis
Under physiological conditions, the endothelium, through 
the synthesis of the key messenger nitric oxide (NO) by 
endothelial NO synthase (eNOS), regulates several physiological 
processes such as vascular tone, arterial stiffness, blood 
pressure, peripheral vascular resistance, and platelet activity, 
and it also exerts important antiatherosclerotic effects, 
including the inhibition of leukocyte adhesion to the arterial 
wall and the prevention of vascular smooth muscle cell 
proliferation.13,14 According to the ‘inflammatory theory’ of 
atherosclerosis, the excessive production of pro-atherogenic 
cytokines, particularly tumour necrosis factor-alpha (TNF-α), 
interleukin-1 (IL-1), and interleukin-6 (IL-6), alters the structural 
and functional integrity of the endothelium, favouring the 
formation and progression of the atherosclerotic plaque.4,8 
This has significant biological, as well as clinical, implications as 
both the presence and the severity of endothelial dysfunction, 
either singly or in combination with other markers of arterial 
dysfunction, independently predict adverse cardiovascular 
outcomes.15 By contrast, there is good evidence that other 
cytokines, particularly transforming growth factor-β (TGF-β), 
interleukin-10 (IL-10), and interleukin-35 (IL-35), exert protective 
effects against atherogenesis, including the down-regulation 
of TNF-α and intercellular adhesion molecule-1 (ICAM-1) in 
endothelial cells.16,17
Current research focuses on the effects of targeted cytokine 
therapies, that is, anti-IL-1 agents, on surrogate markers 
of atherosclerosis as well as cardiovascular morbidity and 
mortality end-points in clinical trials.7–9,18 The introduction 
of such therapies would represent a significant milestone in 
the management of cardiovascular risk. However, the agents 
currently under investigation, albeit marketed for other 
indications (e.g. the biologic agents adalimumab, etanercept, 
canakinumab, anakinra, and tocilizumab), are characterized by 
relatively high costs and potentially serious toxicity.18–22 These 
issues might limit their routine use in a significant number 
of cardiovascular patients. Studies are also investigating the 
effects of currently marketed anti-inflammatory drugs, with 
a wider spectrum of effects on inflammatory and immune 
pathways, on atherosclerosis and cardiovascular risk.7–9 The 
following sections will discuss the available evidence regarding 
the effects of the DMARD methotrexate on cardiovascular 
outcomes and surrogate markers of atherosclerosis and 
cardiovascular risk.
Methotrexate and cardiovascular 
risk: epidemiological evidence
Methotrexate, an analogue of the B-vitamin folic acid, is a first-
line synthetic DMARD that is routinely used, at doses between 
7.5 and 25 mg weekly, in the management of rheumatoid 
arthritis and other autoimmune, chronic inflammatory 
conditions.23,24 Epidemiological studies have shown that, 
when compared to other synthetic DMARDs, methotrexate 
significantly reduces all-cause mortality in patients with 
rheumatoid arthritis.25,26 Although the mechanisms responsible 
for this protective effect are unknown, a study has also 
reported a significant reduction in cardiovascular mortality 
(hazard ratio [HR] 0.3, 95% confidence interval [CI]: 0.2–0.7), but 
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or death from coronary heart disease) with pravastatin 
treatment versus placebo was 0.69 (95% CI: 0.57–0.83).48
Methotrexate and cardiovascular 
risk factors
Several in vitro and in vivo studies have investigated the effects 
of methotrexate on traditional (e.g. dyslipidaemia, diabetes, 
hypertension) and emerging (e.g. endothelial dysfunction and 
arterial stiffness) cardiovascular risk factors.
Contrasting results have been reported on the capacity of 
methotrexate to influence the activity of the cholesterol 
efflux protein and the concentrations of total cholesterol and 
different lipoproteins.49–60 More recently, a study in cholesterol-
fed rabbits receiving combined treatment with lipid core 
nanoparticles containing paclitaxel and methotrexate showed 
a significant regression of aortic plaque and intima areas. This 
was associated with a reduction of macrophage presence in 
aortic lesions, matrix metalloproteinase 9, and TNF-α gene 
expression when compared to control animals.61
In in vitro studies, treatment with methotrexate increased 
the expression of the glucose transporter type 4 (GLUT4) in a 
mouse model of diabetes. This was associated with a significant 
reduction in serum glucose and insulin concentrations.62 
Human studies have shown significant reductions in insulin 
concentrations,63 but not glucose concentrations,51,60,64–67 
during methotrexate treatment. Contrasting results have 
been reported on the effects of methotrexate on glycated 
haemoglobin concentrations.66–68
Cross-sectional human studies have shown trends towards 
lower systolic and diastolic blood pressure values in patients 
with rheumatoid arthritis treated with methotrexate when 
compared to other DMARDs or no treatment.51,69 Similar trends 
have been reported in prospective studies, albeit no placebo 
group was included.70–72 Trends towards a lower prevalence 
of hypertension in patients with rheumatoid arthritis treated 
with methotrexate, when compared to other DMARDs or 
no treatment, have also been reported, though no formal 
statistical analysis was presented.73 In a recent repeated cross-
sectional study, patients with rheumatoid arthritis treated with 
methotrexate, with or without other DMARDs, had significantly 
lower clinic and 24-ambulatory systolic and diastolic blood 
pressure and pulse-wave velocity, a marker of arterial stiffness, 
when compared to patients treated with other DMARDs, but not 
methotrexate (n=30).74 The association between methotrexate 
use and blood pressure was mediated, in univariate but not 
in multivariate analysis, by a single-nucleotide polymorphism 
(SNP) of the adenosine triphosphate (ATP)-binding cassette 
efflux transporter gene ABCG2 (rs2231142).75 In further analyses, 
methotrexate treatment prevented the temporal increase in 
blood pressure mediated by arterial stiffness.76
In animal studies, treatment with methotrexate caused 
a significant impairment of endothelium-dependent 
(acetylcholine-mediated), but not endothelium-independent 
not non-cardiovascular mortality (HR 0.6, 95% CI: 0.2–1.2), with 
methotrexate use.25
Rheumatoid arthritis can be regarded as a human model of 
chronic systemic inflammation, accelerated atherosclerosis, and 
vascular damage.27 Increased concentrations of pro-atherogenic 
cytokines TNF-α, IL-1, and IL-6 have been well documented in 
patients with rheumatoid arthritis.28 The cardiovascular risk 
in rheumatoid arthritis is about two-fold that of the general 
population and is comparable to the risk in diabetes.29 
However, in addition to inflammation, traditional risk factors 
are also involved in the pathophysiology of atherosclerotic 
cardiovascular disease in rheumatoid arthritis.30 There is 
good evidence that a significant proportion of patients with 
rheumatoid arthritis, even those without prior evidence of 
cardiovascular disease, have endothelial dysfunction, altered 
vascular reactivity, increased platelet activation, dyslipidaemia, 
and insulin resistance.31–35 Furthermore, increased arterial wave 
reflection and arterial stiffness, and a relatively high prevalence 
of hypertension, hypercholesterolaemia, obesity, cigarette 
smoking, type 2 diabetes, and metabolic syndrome, have been 
reported in this group.35–41 From a pathophysiological point 
of view, a sustained increase in arterial wave reflection, arterial 
stiffness, and systolic blood pressure causes a significant increase 
in cardiac afterload. This, in turn, favours the development of 
left ventricular hypertrophy and dysfunction and independently 
predicts cardiovascular morbidity and mortality.42–44
The available evidence supporting the hypothesis that 
methotrexate exerts protective effects against atherosclerotic 
cardiovascular disease in humans, when compared to other 
DMARDs, comes from two systematic reviews and meta-
analyses. The first, in 66,334 patients with rheumatoid arthritis, 
psoriasis, or polyarthritis from ten cohort studies, showed that 
the use of methotrexate was associated with a significantly 
lower risk of total cardiovascular events (risk ratio [RR] 0.79, 95% 
CI: 0.73–0.87, p<0.001) and myocardial infarction (RR 0.82, 95% 
CI: 0.71–0.96, p=0.01). Stronger inverse associations between 
methotrexate and cardiovascular risk were observed in studies 
(n=6) that adjusted for underlying disease severity (RR 0.64, 
95% CI: 0.43–0.95) and those (n=4) that adjusted for treatment 
with other DMARDs (RR 0.73, 95% CI: 0.63–0.84).45 The second 
systematic review and meta-analysis reported a significant 
reduction in total cardiovascular events with methotrexate 
treatment, when compared to other DMARDs, in eight studies 
of 65,736 patients with rheumatoid arthritis (RR 0.72, 95% 
CI: 0.57–0.91, p=0.007). A significant reduction in the risk of 
myocardial infarction was also observed in a subset of studies 
(n=3, RR 0.81, 95% CI: 0.68–0.96).46 It is important to emphasize 
that the magnitude of cardiovascular risk reduction observed 
with methotrexate treatment is similar to that reported in 
landmark trials of cardioprotective drugs in high-risk patients. 
For example, in the Heart Outcomes Prevention Evaluation 
study, the relative risk of total cardiovascular events with the 
ACE inhibitor ramipril versus placebo was 0.78 (95% CI: 0.70–
0.86).47 In the West of Scotland Coronary Prevention Study, the 
relative risk of coronary events (non-fatal myocardial infarction 
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(nitroprusside-mediated), vasodilatation.77 By contrast, no 
significant changes in endothelial function were observed 
in patients with rheumatoid arthritis or psoriasis treated 
with methotrexate.70,78 Other studies reported a significant 
improvement in endothelial function with methotrexate 
in patients with rheumatoid arthritis and other types of 
inflammatory arthritis.79,80
A significant reduction in measures of arterial stiffness was 
observed in patients with rheumatoid arthritis treated with 
methotrexate and infliximab, but not with methotrexate 
alone.71 By contrast, another study reported no significant 
changes in arterial stiffness with methotrexate.81
Despite the conflicting results reported in several studies, the 
available evidence suggests that methotrexate might exert 
beneficial effects on some measures of cardiovascular risk, 
particularly insulin resistance, blood pressure, and, possibly, 
arterial stiffness.
Putative mechanisms mediating 
the effects of methotrexate 
against atherosclerosis
A number of mechanisms might account for the potential 
antiatherosclerotic, blood pressure lowering, and 
vasculoprotective effects of methotrexate, particularly cytokine 
modulation, adenosine accumulation, and activation of 5’ 
adenosine monophosphate-activated protein kinase.
Cytokine modulation
Methotrexate has been shown in vitro to increase the release of 
soluble TNF receptor p75 from the cell surface, with potential 
inhibition of the pro-inflammatory effects of TNF-α.82,83 In other 
studies, methotrexate treatment prevented the TNF-α-induced 
expression of ICAM-1 and vascular cell adhesion molecule 1, 
both involved in favouring the adhesion of leukocytes to the 
endothelium in the early stages of atherosclerosis.84 In animal 
studies, methotrexate significantly reduced the circulating 
concentrations of IL-6 and TNF-α. This was paralleled by a 
significant increase in endothelium-dependent vasodilatation 
and a reduction in vascular cell adhesion molecule 1.85 In another 
study, the expression of IL-6 and TNF-α was also significantly 
reduced by methotrexate treatment. These effects were 
associated with an improvement in endothelium-dependent 
vasodilation in rat aorta.86 The inhibitory effects of methotrexate 
on TNF-α, IL-1, and IL-6 have also been recently reported in 
human macrophages.87 Notably, there is also preliminary 
evidence that the effects of methotrexate on pro-inflammatory 
cytokines are associated with a reduction in plaque burden. 
Four-week intravenous administration of methotrexate-loaded 
spherical polymeric nanoconstructs significantly reduced the 
production of IL-6 and TNF-α in apolipoprotein E–deficient 
(ApoE-/-) mice receiving high-fat diet. These effects were 
associated with a 50% reduction in plaque burden.88
Other studies have reported beneficial effects of methotrexate 
treatment on antiatherogenic cytokines. In 24 patients with 
plaque psoriasis, 12-week treatment with subcutaneous 
methotrexate caused a trend towards an increase in IL-10, 
but not TGF-β, concentrations.60 In patients with chronic 
heart failure, 12-week treatment with methotrexate 
significantly increased the plasma concentrations of IL-10.89 A 
significant increase in IL-10 concentrations after 4- or 12-week 
methotrexate treatment was reported in rabbit models of in-
stent neo-atherosclerosis and cardiac allograft vasculopathy, 
and in post-myocarditis rats.90–92 Methotrexate treatment 
has also been shown to increase the local adipose tissue 
concentrations of IL-10 in obese mice fed with high-fat diet.93
Adenosine accumulation and activation of 
5’ adenosine monophosphate-activated 
protein kinase
The intracellular polyglutamate forms of methotrexate inhibit 
the activity of the enzyme aminoimidazole carboxamide 
ribonucleotide (AICAR) transformylase (ATIC).94 The consequent 
accumulation of the substrate AICAR, in turn, inhibits the 
enzymes adenosine deaminase and adenosine monophosphate 
deaminase, involved in the catabolism of adenosine.94 Adenosine 
exerts blood pressure lowering effects through increased eNOS, 
direct vasodilation, and central nervous system pathways.95–97 
Furthermore, in human studies, the pharmacological inhibition 
of adenosine receptors, particularly A1 and A2A,
98 has been 
shown to increase blood pressure and arterial stiffness.99 
There is also evidence that adenosine A2B receptor activation 
prevents the formation of atherosclerotic lesions and reduces the 
plasma concentrations of cholesterol and triglycerides, possibly 
through the reduced activation of the transcription factor sterol 
regulatory element-binding protein 1 in the liver.100,101
Both AICAR and adenosine monophosphate deaminase 
activate the 5’ adenosine monophosphate-activated protein 
kinase (AMPK).102 AMPK protects endothelial cells against 
oxidative stress and apoptosis and inhibits vascular smooth 
muscle cell proliferation.103–105 There is increasing evidence 
that AICAR and/or AMPK activation stimulates NO synthesis 
in the endothelium, enhances endothelium-dependent 
and endothelium-independent vasodilation, reduces blood 
pressure, prevents vessel restenosis, and increases cholesterol 
efflux capacity.106–111 Furthermore, AMPK stimulates cellular 
glucose uptake, through GLUT-1 and GLUT-4 transporters, 
and glycolysis, providing beneficial effects on glucose 
homeostasis.112
Current and future research 
directions
Further experimental and clinical studies are required to 
support the repurposing of methotrexate for the management 
of patients with atherosclerotic cardiovascular disease. 
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In particular, studies should investigate the effects of 
methotrexate on different cardiovascular end-points and also 
determine the role of pro- and antiatherogenic cytokines, 
adenosine, AMPK activation, methotrexate polyglutamate 
concentrations (a robust marker of methotrexate intracellular 
exposure), and genetic polymorphisms of methotrexate 
transporters and target enzymes,75,113 in mediating these 
effects. While appropriately powered trials, using either 
placebo or other DMARDs as comparator, should ultimately 
test the hypothesis that methotrexate reduces cardiovascular 
morbidity and mortality both in patients with and without 
autoimmune disorders, a number of trials addressing this 
issue are already in progress or have recently been completed. 
The results of a relatively small (n=84) study have been 
disappointing. The Effects of Methotrexate Therapy on ST 
Segment Elevation Myocardial Infarctions trial (TETHYS, 
clinicaltrials.gov identifier NCT01741558), investigated the role 
of methotrexate in reducing infarct size when administered 
within the first 6 hours of admission for ST-elevation myocardial 
infarction. Methotrexate was given as intravenous bolus, 
0.05 mg/kg, immediately before percutaneous coronary 
intervention, followed by 0.05 mg/kg/hr for 6 hours. The infarct 
size in patients treated with methotrexate was not significantly 
different from that of patients receiving placebo. Furthermore, 
in univariate analysis, the left ventricular ejection at 3 months 
was lower in the methotrexate group when compared to the 
placebo group.114 Another study is currently investigating the 
effects of methotrexate carried by a lipid nanoemulsion, 40 mg/
m2 single dose intravenously, on left ventricular remodelling 
in 50 patients with anterior wall ST-elevation myocardial 
infarction (clinicaltrials.gov identifier NCT03516903). The 
recruitment for the Cardiovascular Inflammation Reduction 
Trial (CIRT, clinicaltrials.gov identifier NCT01594333), a large 
randomized placebo-controlled trial investigating whether 
methotrexate, 15–20 mg weekly as single oral dose, reduces a 
composite primary end-point of myocardial infarction, stroke, 
and cardiovascular death in 7,000 patients with type 2 diabetes 
or metabolic syndrome and stable coronary artery disease, has 
been prematurely stopped in April 2018. The trial has accrued 
enough data to answer the main question of the study and it 
is anticipated that the results will be presented by the end of 
2018.115 The Inflammation and Coronary Endothelial Function 
in Patients with Coronary Artery Disease Trial (clinicaltrials.gov 
identifier NCT02366091) is investigating the effect of 15 mg 
oral methotrexate weekly, colchicine, and their combination on 
coronary endothelial function in 120 patients with established 
ischaemic heart disease. Furthermore, the Methotrexate, Blood 
Pressure and Arterial Function Study (clinicaltrials.gov identifier 
NCT03254589) is investigating the effects of methotrexate 
treatment, 7.5–25 mg weekly, on clinical and 24-hour peripheral 
and central blood pressure in 124 patients with rheumatoid 
arthritis. The results of these studies will provide important 
additional information to support, or refute, the possible 
role of methotrexate in the management of patients with 
atherosclerotic cardiovascular disease.
Practical considerations with 
the use of methotrexate in 
cardiovascular risk management
Methotrexate is a relatively old drug that has been used, at 
high doses, for the treatment of different types of cancer and, 
more recently, at lower doses, for the treatment of several 
autoimmune disease states.116–118 Treatment with high- and 
low-dose methotrexate is associated with gastroenterological, 
haematological, renal, neurological, pulmonary, and 
mucocutaneous toxicity of different severity.119,120 However, 
with appropriate dosing and monitoring, the main side effects 
of methotrexate, particularly hepatic, gastrointestinal, and 
haematological toxicity, are infrequent and rarely severe. 
In a naturalistic study of 673 patients with inflammatory 
arthritis receiving methotrexate, mainly rheumatoid arthritis, 
74% remained on treatment after 5 years. Methotrexate was 
stopped in 10.7% because of inefficacy or patient choice. 
Serious adverse events included liver abnormalities in 5.5% and 
haematological abnormalities in a further 5.5%.121 In the CareRA 
study of 379 patients with rheumatoid arthritis randomized 
to 1-year treatment with methotrexate + other DMARDs 
and/or corticosteroids, 2.1% reported serious adverse events.122 
The safety profile of methotrexate in these studies compares 
favourably with trials of conventional cardioprotective drugs, 
for example, antihypertensive agents, in patient populations 
without autoimmune conditions. For example, in the Systolic 
Blood Pressure Intervention Trial in 9,069 patients with high 
cardiovascular risk, 9.8% (intensive treatment arm) and 7.2% 
(standard treatment arm) had serious adverse events.123 In the 
Ongoing Telmisartan Alone and in Combination with Ramipril 
Global Endpoint Trial in 25,620 patients with vascular disease or 
high-risk diabetes, serious adverse events leading to treatment 
discontinuation occurred in 7.2% of those randomized to 
ramipril, 5.1% of those randomized to telmisartan, and 12.0% of 
those randomized to combination treatment.124
A potential advantage associated with methotrexate treatment is 
the once-weekly administration, either orally or subcutaneously. 
By contrast, virtually all cardiovascular drugs currently used 
require daily administration. The less-intense treatment schedule 
with methotrexate has the potential to increase treatment 
adherence, which remains a significant issue in the routine 
management of patients at high cardiovascular risk. For example, 
a recent study showed that only 49% of older patients after an 
acute myocardial infarction (n=90,869) were adherent to three 
standard therapies: ACE inhibitors or ARBs, beta-blockers, and 
statins. Notably, the lack of adherence to these therapies was 
independently associated with increased mortality (HR 1.65, 95% 
CI: 1.54–1.76).125 Similarly, a systematic review and meta-analysis 
reported that the non-adherence rate to secondary prevention 
treatment after a stroke is 30.9% (95% CI: 26.8–35.3).126
Repurposing methotrexate for cardiovascular risk 
management, at doses similar to those currently prescribed 
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in patients with autoimmune disorders, would also be highly 
cost effective. For example, in Australia the Prescribing Benefits 
Scheme cost of methotrexate 7.5–25 mg once a week is 
$94.8–109.68/year per individual patient. This is less than half 
of that of atorvastatin ($222.48–258.60/year) and perindopril 
($222.60–256.68/year), the most commonly prescribed statin 
and ACE inhibitor in Australia, respectively. The corresponding 
cost figures for methotrexate, atorvastatin, and perindopril  
in the United Kingdom are £8.35–55.64/year, £7.95–22.42/year,  
and £64.60–80.18/year, respectively. Notably, the yearly costs 
of anakinra, a marketed IL-1 antagonist for the treatment 
of rheumatoid arthritis currently under investigation as 
antiatherosclerotic agent, are $514.91 in Australia and £9,568.21 
in the United Kingdom.
Conclusions
The recognition that atherosclerosis is a chronic inflammatory 
disease of the arterial wall and that significant residual 
cardiovascular risk exists in a substantial number of patients 
despite maximal treatment with established drugs such as 
statins, beta-blockers, antiplatelets, anticoagulants, ACE 
inhibitors, and ARBs, justifies the need for novel, effective 
therapies that target multiple pathways, including inflammation. 
Recent studies have highlighted the beneficial effects of 
currently marketed anti-inflammatory drugs, such as colchicine 
and hydroxychloroquine, in reducing cardiovascular events 
in patients with stable coronary artery disease and in patients 
with rheumatoid arthritis.127–130 Methotrexate has also the 
potential to be repurposed for the management of patients with 
atherosclerotic cardiovascular disease and residual cardiovascular 
risk treated with currently recommended cardioprotective 
agents, in view of a unique combination of anti-inflammatory 
and, possibly, blood pressure lowering and vasculoprotective 
effects. In this context, the identification of the patients who 
are most likely to benefit from methotrexate treatment might 
require additional stratification by measuring pro-atherogenic, 
and possibly antiatherogenic, cytokine concentrations. However, 
only after the completion of several prospective studies 
investigating the effects on surrogate cardiovascular end-points 
as well as morbidity and mortality, can the exact therapeutic role 
of methotrexate be established in this context.
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